Chronic Lymphocytic Leukemia Research Consortuim
CRC Research CRC Sites Clinical Trials For Patients Biorepository Publications & News How to Donate

Clinical Trials

The CRC is developing new and innovative curative strategies for CLL.

CRC Trials

CRC clinical investigators are participating in the listed clinical trials. Site participation varies. In order to find out more about the clinical trials occurring at the CRC site nearest you, please click on CRC Sites. The research nurses/coordinators will be able to assist you with the details of these clinical trials and others being conducted at each local site. What is a Clinical Trial?

Non Intervention Protocols:

CRC000 CLL Research Consortium Tissue Core Sample Collection Study and Familial: This Study Sample Collection. The CRC tissue core study is one of the world's largest repositories of CLL materials. The collection of samples from patients around the world enable researchers to uncover CLL's mechanisms of action, with the hopeful result of developing curative strategies for patient with CLL. Click Here to read the CRC000 Tissue Core Abstract.

STATUS: Active Accrual

Intervention Protocol, Therapeutic:

CRC022 Revlimid® and Rituximab for Relapse and Refractory Patients: A Two-Arm, CLL Research Consortium (CRC022) Multi-Center Trial of Revlimid and Rituximab, for the Treatment of relapsed or refractory Patients with Chronic Lymphocytic Leukemia [UCSD-100205]

The primary objective of this study is to determine the overall response rate (complete response (CR) and partial response (PR)) of the combination of Revlimid® and rituximab in previously treated CLL patients for those age 65 years and above and those younger than 65. Click here to read the CRC022 Abstract.

STATUS: Active Accrual

Intervention Protocol, Therapeutic:

CRC025 Autologous stem cell transplantation (SCT): CRC clinical site investigators are collaborating with CALBG and CTN on the first multi-center trial of allo-SCT for patients with CLL

STATUS: Pending

Intervention Protocol, Therapeutic:

CRC027 Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL): The CLL Research Consortium (CRC) is conducting a phase II clinical trial of Ofatumumab in combination with High-Dose Methylprednisolone (HDMP). Patients who have relapsed/refractory CLL and require therapy as per iwCLL guidelines will be eligible. Subjects will receive a treatment with ofatumumab and HDMP for three consecutive 4 week cycles.

The primary endpoint is to determine the complete response (CR) to therapy and the secondary endpoints will assess the safety and tolerability of the regimen, the impact of the treatment on progression free, treatment free, overall survival, and pharmacokinetics of ofatumumab. Patients will receive allopurinol for tumor-lysis prophylaxis and antimicrobial prophylaxis.

STATUS: Closed to Accrual

Intervention Protocol, Therapeutic:

CRC014 Revlimid® and Rituximab: A Two-Arm, Multi-center trial of Revlimid® and Rituximab, for First-Line Treatment in Patients with B-cell Chronic Lymphocytic Leukemia (CLL) Brief Description: The study is a two-arm, multi-center trial of Revlimid® and Rituximab, for the frontline treatment of patients with Chronic Lymphocytic Leukemia (CLL) designed and conducted by the CLL Research Consortium (CRC).

The purpose of this study is to determine the response rate of the combination of Revlimid® and Rituximab in previously untreated CLL patients in two arms- those aged 65 years and above and those younger than 65. Secondary objectives will evaluate the safety of the combination of Revlimid® and Rituximab, response duration, improvement in hematologic parameters, and the prognostic role of the tumor flare reaction.

All patients will have assessment of known prognostic factors for CLL as well as novel prognostic factors will be evaluated for predicting response to treatment. Biologic corollary studies are designed to evaluate the mechanism of Revlimid® in CLL and the combination of Revlimid® and Rituximab. Click here to read the CRC014 Abstract.


Intervention Protocol, Therapeutic:

CRC012 OFAR II: Phase I/II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients with Richter's Transformation, Prolymphocytic Leukimia or Refractory / Relapsed B-Cell Chronic Lymphocytic Leukemia. Click here to read the crc012 Abstract.


Intervention Protocol, NonTherapeutic:

CRC011 Heavy Water: This is a Kinetic Biomarker for study for Chronic Lymphocytic Leukemia (CLL). The fundamental disorder in cancer is altered cell kinetics (cell proliferation and/or death). Preliminary data suggests this is a safe and non-toxic method for accurately measuring cell proliferation and turnover in vivo in B-CLL may prove to be of significant prognostic utility in patients with early stage disease. After heavy water (deuterated water, 2H2O) is orally administered, deuterium (2H) is incorporated into the deoxyribose (dR) moiety of purine deoxyribonucleotides in DNA of dividing cells. Blood or bone marrow is obtained at appropriate time points. DNA is isolated, and the amount of 2H incorporated into DNA is quantified by mass spectrometry, allowing for a measure of cellular proliferation.

There is no radioactivity involved, and there are no known risks of heavy water at the doses that we administer.


Planned CRC Trials

CRC Trial Number Title Phase/Population



Phase II, Relapsed



Phase II, Relapsed


Ofatumumab, Pentostatin, and Cyclophosphamide (PCO)

Phase II, Frontline/Untreated Patients



Phase I/IIa, Relapsed



Phase II, Patients with a 11q deletion and have relapsed


Flavopiridol + Ofatumumab



Epigallocatechin Gallate (EGCG)

Phase II, Frontline/Untreated Patients



Phase II, Untreated Patients


SCH 727965

Phase II, Relapsed


CAL-101 + Ofatumumab

Phase II, Frontline


ISF35 + Lenalidomide

Phase II, Relapsed



Phase I, TBD



Phase I, TBD


contact us home